NASDAQ:LUMO

Lumos Pharma Competitors

$12.00
+0.21 (+1.78 %)
(As of 04/21/2021 04:30 PM ET)
Add
Compare
Today's Range
$11.56
Now: $12.00
$12.14
50-Day Range
$10.90
MA: $12.68
$14.97
52-Week Range
$7.85
Now: $12.00
$36.72
Volume23,904 shs
Average Volume59,113 shs
Market Capitalization$99.98 million
P/E RatioN/A
Dividend YieldN/A
Beta1.69

Competitors

Lumos Pharma (NASDAQ:LUMO) Vs. URGN, FHTX, NATR, NBRV, FULC, and ATHX

Should you be buying LUMO stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Lumos Pharma, including UroGen Pharma (URGN), Foghorn Therapeutics (FHTX), Nature's Sunshine Products (NATR), Nabriva Therapeutics (NBRV), Fulcrum Therapeutics (FULC), and Athersys (ATHX).

UroGen Pharma (NASDAQ:URGN) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

Profitability

This table compares UroGen Pharma and Lumos Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
UroGen PharmaN/A-92.22%-81.71%
Lumos Pharma-2,053.30%-10.58%-7.83%

Risk & Volatility

UroGen Pharma has a beta of 1.32, suggesting that its share price is 32% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.69, suggesting that its share price is 69% more volatile than the S&P 500.

Valuation & Earnings

This table compares UroGen Pharma and Lumos Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
UroGen Pharma$20,000.0020,593.99$-105,150,000.00($5.12)-3.85
Lumos Pharma$940,000.00106.37$-42,990,000.00($9.27)-1.29

Lumos Pharma has higher revenue and earnings than UroGen Pharma. UroGen Pharma is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings and recommmendations for UroGen Pharma and Lumos Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
UroGen Pharma00303.00
Lumos Pharma00603.00

UroGen Pharma presently has a consensus price target of $37.3333, indicating a potential upside of 89.41%. Lumos Pharma has a consensus price target of $33.50, indicating a potential upside of 179.17%. Given Lumos Pharma's higher probable upside, analysts clearly believe Lumos Pharma is more favorable than UroGen Pharma.

Institutional & Insider Ownership

71.6% of UroGen Pharma shares are held by institutional investors. Comparatively, 43.8% of Lumos Pharma shares are held by institutional investors. 12.0% of UroGen Pharma shares are held by insiders. Comparatively, 15.9% of Lumos Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Lumos Pharma beats UroGen Pharma on 8 of the 13 factors compared between the two stocks.

Foghorn Therapeutics (NASDAQ:FHTX) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Foghorn Therapeutics and Lumos Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Foghorn TherapeuticsN/AN/AN/A
Lumos Pharma-2,053.30%-10.58%-7.83%

Valuation and Earnings

This table compares Foghorn Therapeutics and Lumos Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Foghorn TherapeuticsN/AN/AN/AN/AN/A
Lumos Pharma$940,000.00106.37$-42,990,000.00($9.27)-1.29

Foghorn Therapeutics has higher earnings, but lower revenue than Lumos Pharma.

Analyst Ratings

This is a breakdown of current recommendations for Foghorn Therapeutics and Lumos Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Foghorn Therapeutics00403.00
Lumos Pharma00603.00

Foghorn Therapeutics presently has a consensus price target of $24.6667, indicating a potential upside of 105.90%. Lumos Pharma has a consensus price target of $33.50, indicating a potential upside of 179.17%. Given Lumos Pharma's higher probable upside, analysts clearly believe Lumos Pharma is more favorable than Foghorn Therapeutics.

Institutional and Insider Ownership

43.8% of Lumos Pharma shares are owned by institutional investors. 15.9% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Lumos Pharma beats Foghorn Therapeutics on 5 of the 8 factors compared between the two stocks.

Nature's Sunshine Products (NASDAQ:NATR) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Profitability

This table compares Nature's Sunshine Products and Lumos Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nature's Sunshine Products4.39%11.61%7.14%
Lumos Pharma-2,053.30%-10.58%-7.83%

Volatility & Risk

Nature's Sunshine Products has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Valuation and Earnings

This table compares Nature's Sunshine Products and Lumos Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nature's Sunshine Products$362.21 million1.06$6.76 millionN/AN/A
Lumos Pharma$940,000.00106.37$-42,990,000.00($9.27)-1.29

Nature's Sunshine Products has higher revenue and earnings than Lumos Pharma.

Analyst Ratings

This is a breakdown of current recommendations for Nature's Sunshine Products and Lumos Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nature's Sunshine Products0000N/A
Lumos Pharma00603.00

Lumos Pharma has a consensus price target of $33.50, indicating a potential upside of 179.17%. Given Lumos Pharma's higher probable upside, analysts clearly believe Lumos Pharma is more favorable than Nature's Sunshine Products.

Institutional and Insider Ownership

78.3% of Nature's Sunshine Products shares are owned by institutional investors. Comparatively, 43.8% of Lumos Pharma shares are owned by institutional investors. 16.0% of Nature's Sunshine Products shares are owned by company insiders. Comparatively, 15.9% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Nature's Sunshine Products beats Lumos Pharma on 8 of the 12 factors compared between the two stocks.

Nabriva Therapeutics (NASDAQ:NBRV) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, risk, earnings, dividends and institutional ownership.

Institutional and Insider Ownership

23.7% of Nabriva Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Lumos Pharma shares are owned by institutional investors. 2.8% of Nabriva Therapeutics shares are owned by company insiders. Comparatively, 15.9% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Profitability

This table compares Nabriva Therapeutics and Lumos Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Nabriva Therapeutics-1,682.55%-129.80%-71.67%
Lumos Pharma-2,053.30%-10.58%-7.83%

Volatility & Risk

Nabriva Therapeutics has a beta of 1.91, suggesting that its stock price is 91% more volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Valuation and Earnings

This table compares Nabriva Therapeutics and Lumos Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nabriva Therapeutics$9.48 million40.92$-82,760,000.00($11.20)-0.14
Lumos Pharma$940,000.00106.37$-42,990,000.00($9.27)-1.29

Lumos Pharma has lower revenue, but higher earnings than Nabriva Therapeutics. Lumos Pharma is trading at a lower price-to-earnings ratio than Nabriva Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current recommendations for Nabriva Therapeutics and Lumos Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Nabriva Therapeutics01102.50
Lumos Pharma00603.00

Nabriva Therapeutics presently has a consensus price target of $6.00, indicating a potential upside of 287.10%. Lumos Pharma has a consensus price target of $33.50, indicating a potential upside of 179.17%. Given Nabriva Therapeutics' higher probable upside, research analysts clearly believe Nabriva Therapeutics is more favorable than Lumos Pharma.

Summary

Lumos Pharma beats Nabriva Therapeutics on 9 of the 14 factors compared between the two stocks.

Fulcrum Therapeutics (NASDAQ:FULC) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Institutional & Insider Ownership

72.5% of Fulcrum Therapeutics shares are owned by institutional investors. Comparatively, 43.8% of Lumos Pharma shares are owned by institutional investors. 30.3% of Fulcrum Therapeutics shares are owned by company insiders. Comparatively, 15.9% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Fulcrum Therapeutics and Lumos Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Fulcrum TherapeuticsN/A-71.94%-56.24%
Lumos Pharma-2,053.30%-10.58%-7.83%

Risk and Volatility

Fulcrum Therapeutics has a beta of 0.94, suggesting that its stock price is 6% less volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Valuation & Earnings

This table compares Fulcrum Therapeutics and Lumos Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fulcrum TherapeuticsN/AN/A$-82,680,000.00($8.13)-1.42
Lumos Pharma$940,000.00106.37$-42,990,000.00($9.27)-1.29

Lumos Pharma has higher revenue and earnings than Fulcrum Therapeutics. Fulcrum Therapeutics is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings for Fulcrum Therapeutics and Lumos Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Fulcrum Therapeutics11702.67
Lumos Pharma00603.00

Fulcrum Therapeutics presently has a consensus target price of $19.00, indicating a potential upside of 64.93%. Lumos Pharma has a consensus target price of $33.50, indicating a potential upside of 179.17%. Given Lumos Pharma's stronger consensus rating and higher probable upside, analysts plainly believe Lumos Pharma is more favorable than Fulcrum Therapeutics.

Summary

Lumos Pharma beats Fulcrum Therapeutics on 7 of the 13 factors compared between the two stocks.

Athersys (NASDAQ:ATHX) and Lumos Pharma (NASDAQ:LUMO) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, risk, valuation, profitability, institutional ownership and earnings.

Profitability

This table compares Athersys and Lumos Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
AthersysN/A-176.56%-112.67%
Lumos Pharma-2,053.30%-10.58%-7.83%

Valuation & Earnings

This table compares Athersys and Lumos Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Athersys$5.63 million66.87$-44,580,000.00($0.29)-5.97
Lumos Pharma$940,000.00106.37$-42,990,000.00($9.27)-1.29

Lumos Pharma has lower revenue, but higher earnings than Athersys. Athersys is trading at a lower price-to-earnings ratio than Lumos Pharma, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

27.9% of Athersys shares are owned by institutional investors. Comparatively, 43.8% of Lumos Pharma shares are owned by institutional investors. 12.6% of Athersys shares are owned by company insiders. Comparatively, 15.9% of Lumos Pharma shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Athersys has a beta of -1.54, suggesting that its stock price is 254% less volatile than the S&P 500. Comparatively, Lumos Pharma has a beta of 1.69, suggesting that its stock price is 69% more volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Athersys and Lumos Pharma, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Athersys00403.00
Lumos Pharma00603.00

Athersys presently has a consensus target price of $9.00, indicating a potential upside of 420.23%. Lumos Pharma has a consensus target price of $33.50, indicating a potential upside of 179.17%. Given Athersys' higher probable upside, equities analysts plainly believe Athersys is more favorable than Lumos Pharma.

Summary

Lumos Pharma beats Athersys on 8 of the 13 factors compared between the two stocks.


Lumos Pharma Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
UroGen Pharma logo
URGN
UroGen Pharma
1.8$19.71+5.0%$391.19 million$20,000.00-3.08
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$11.98+11.4%$390.63 millionN/A0.00Lockup Expiration
Nature's Sunshine Products logo
NATR
Nature's Sunshine Products
1.0$19.38+1.7%$390.18 million$362.21 million23.35
Nabriva Therapeutics logo
NBRV
Nabriva Therapeutics
1.3$1.55+5.2%$387.88 million$9.48 million-0.26
Fulcrum Therapeutics logo
FULC
Fulcrum Therapeutics
1.7$11.52+1.0%$380.30 millionN/A-4.00
Athersys logo
ATHX
Athersys
1.3$1.73+5.2%$376.47 million$5.63 million-4.68Analyst Upgrade
Cue Biopharma logo
CUE
Cue Biopharma
1.3$12.85+3.9%$376.14 million$3.46 million-8.18
Syros Pharmaceuticals logo
SYRS
Syros Pharmaceuticals
1.3$6.13+0.8%$374.77 million$1.98 million-3.69News Coverage
Athenex logo
ATNX
Athenex
1.6$4.07+2.0%$372.89 million$101.23 million-2.79Gap Up
Spruce Biosciences logo
SPRB
Spruce Biosciences
1.6$15.93+0.4%$369.80 millionN/A0.00High Trading Volume
BeyondSpring logo
BYSI
BeyondSpring
1.2$9.44+0.7%$369.50 millionN/A-4.63
Sesen Bio logo
SESN
Sesen Bio
1.2$2.43+10.3%$369.26 millionN/A-5.52
DURECT logo
DRRX
DURECT
1.4$1.69+5.3%$363.52 million$29.56 million-33.79
Paratek Pharmaceuticals logo
PRTK
Paratek Pharmaceuticals
1.5$8.02+3.4%$363.42 million$16.54 million-3.26
MEI Pharma logo
MEIP
MEI Pharma
1.7$3.38+4.7%$362.34 million$28.91 million-5.63
Aeglea BioTherapeutics logo
AGLE
Aeglea BioTherapeutics
1.7$7.78+3.5%$360.60 million$3.89 million-4.07
Spero Therapeutics logo
SPRO
Spero Therapeutics
1.5$13.30+8.1%$360.54 million$18.15 million-3.13
BELLUS Health logo
BLU
BELLUS Health
1.7$4.52+2.4%$354.08 million$30,000.00-7.66
Oncorus logo
ONCR
Oncorus
1.7$13.89+1.9%$349.27 millionN/A0.00
Verrica Pharmaceuticals logo
VRCA
Verrica Pharmaceuticals
1.6$13.73+1.1%$345.49 millionN/A-10.40
Theratechnologies logo
THTX
Theratechnologies
1.1$3.56+0.8%$336.89 million$63.22 million-11.48Analyst Report
Tonix Pharmaceuticals logo
TNXP
Tonix Pharmaceuticals
1.8$1.03+2.0%$332.02 millionN/A-0.29Gap Up
BioDelivery Sciences International logo
BDSI
BioDelivery Sciences International
2.1$3.42+4.1%$330.83 million$111.39 million24.43
Frequency Therapeutics logo
FREQ
Frequency Therapeutics
1.5$9.76+2.3%$326.06 million$28.95 million-13.94
Homology Medicines logo
FIXX
Homology Medicines
1.6$6.71+5.4%$320.60 million$1.67 million-2.46
Hookipa Pharma logo
HOOK
Hookipa Pharma
1.2$12.30+1.7%$313.98 million$11.94 million-7.50High Trading Volume
Orphazyme A/S logo
ORPH
Orphazyme A/S
1.0$9.52+7.4%$308.28 millionN/A0.00Gap Down
RedHill Biopharma logo
RDHL
RedHill Biopharma
1.4$6.87+4.2%$305.28 million$6.29 million-3.95
ProQR Therapeutics logo
PRQR
ProQR Therapeutics
1.4$6.00+4.2%$301.23 millionN/A-4.88
Wave Life Sciences logo
WVE
Wave Life Sciences
1.8$6.11+3.4%$299.37 million$15.98 million-1.08
Arbutus Biopharma logo
ABUS
Arbutus Biopharma
1.4$3.13+4.5%$288.05 million$6.01 million-2.54News Coverage
CymaBay Therapeutics logo
CBAY
CymaBay Therapeutics
1.6$4.40+5.2%$287.51 millionN/A-4.68
Oncternal Therapeutics logo
ONCT
Oncternal Therapeutics
1.7$6.64+13.4%$283.84 million$2.42 million-5.82
Trevena logo
TRVN
Trevena
1.3$1.75+2.9%$282.23 million$30,000.00-7.61News Coverage
Gap Down
VistaGen Therapeutics logo
VTGN
VistaGen Therapeutics
1.3$1.96+4.1%$280.95 millionN/A-4.08
Sol-Gel Technologies logo
SLGL
Sol-Gel Technologies
1.2$14.19+4.6%$276.08 million$22.90 million-10.67
Immunic logo
IMUX
Immunic
1.8$14.08+8.3%$273.28 millionN/A-4.77Analyst Report
Kamada logo
KMDA
Kamada
1.4$6.11+1.5%$272.02 million$127.19 million12.73
Immunome logo
IMNM
Immunome
1.1$27.25+7.9%$267.67 millionN/A0.00Analyst Upgrade
News Coverage
Infinity Pharmaceuticals logo
INFI
Infinity Pharmaceuticals
1.6$3.00+7.3%$265.92 million$3.05 million-4.23News Coverage
Alpine Immune Sciences logo
ALPN
Alpine Immune Sciences
1.8$11.04+0.2%$263.18 million$1.74 million-7.67
TFF Pharmaceuticals logo
TFFP
TFF Pharmaceuticals
1.4$11.24+0.8%$260.09 millionN/A-4.26
Kezar Life Sciences logo
KZR
Kezar Life Sciences
1.3$5.78+6.6%$259.56 millionN/A-4.62
Mustang Bio logo
MBIO
Mustang Bio
1.6$3.13+3.5%$257.23 millionN/A-2.50Increase in Short Interest
Oramed Pharmaceuticals logo
ORMP
Oramed Pharmaceuticals
1.3$9.22+9.5%$252.10 million$2.71 million-15.90Analyst Report
News Coverage
NextCure logo
NXTC
NextCure
1.6$9.14+1.1%$249.50 million$6.35 million-8.09
TLC
Taiwan Liposome
1.2$5.88+1.2%$247.41 million$6.99 million-7.35
VYNE Therapeutics logo
VYNE
VYNE Therapeutics
1.8$5.15+6.6%$246.89 million$10.64 million-1.37
Ovid Therapeutics logo
OVID
Ovid Therapeutics
1.5$3.59+0.3%$236.06 millionN/A-2.55Analyst Downgrade
News Coverage
9 Meters Biopharma logo
NMTR
9 Meters Biopharma
1.8$1.08+3.7%$233.36 millionN/A0.00
This page was last updated on 4/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.